Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Cardiovascular safety and benefits of GLP-1 receptor agonists

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Cardiovascular risks associated with protease inhibitors for the treatment of HIV

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  2. Safety and tolerability evaluation of erenumab for the preventive treatment of migraine

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Strategies to counter antipsychotic-associated weight gain in patients with schizophrenia

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

Vis graf over relationer

INTRODUCTION: Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RAs) constitute a class of drugs for the treatment of type 2 diabetes, and currently, six different GLP-1RAs are approved. Besides improving glycemic control, the GLP-1RAs have other beneficial effects such as weight loss and a low risk of hypoglycemia. Treatment with the GLP-1RA lixisenatide has been shown to be safe in patients with type 2 diabetes and recent acute coronary syndrome. Furthermore, liraglutide and semaglutide have been shown to reduce cardiovascular (CV) disease (CVD) risk in type 2 diabetes patients with established and/or high risk of CVD. The CV safety of the remaining GLP-1RAs in type 2 diabetes patients with established and/or high risk of CVD remains uncertain, but ongoing CV outcome trials (CVOTs) will elucidate this within a few years. Areas covered: The aim of this review is to provide an overview of the existing GLP-1RAs with a particular focus on their clinical effects on CV risk factors and their CV safety and benefits. Expert opinion: Data on the CV risks and benefits associated with GLP-1RA treatment in patients with type 2 diabetes and high risk of CVD are emerging - and look promising (especially for liraglutide and semaglutide). Data from ongoing CVOTs will be crucial for the positioning of the individual GLP-1RAs in the treatment of patients with type 2 diabetes and high risk of CVD. However, the long-term CV safety and the potential of GLP-1RAs to prevent CVD in type 2 diabetes patients with less risk of CVD (e.g. newly diagnosed patients) remain uncertain.

OriginalsprogEngelsk
TidsskriftExpert Opinion on Drug Safety
Vol/bind16
Udgave nummer3
Sider (fra-til)351-363
Antal sider13
ISSN1474-0338
DOI
StatusUdgivet - mar. 2017

ID: 52661547